<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">15150657</PMID>
        <DateCompleted>
            <Year>2005</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0171-5216</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>130</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cancer research and clinical oncology</Title>
                <ISOAbbreviation>J Cancer Res Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management.</ArticleTitle>
            <Pagination>
                <MedlinePgn>383-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Despite the similarities between the chemotherapeutic management of advanced gestational trophoblastic disease (GTD) and ovarian germ cell tumors, important differences exist between the malignancies, particularly in the use of cisplatin.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Three patients with persistent or recurrent GTD cared for at the Cleveland Clinic received a high-dose chemotherapy program (with stem cell support), one as management for etoposide-associated acute leukemia resulting from her &quot;standard dose&quot; treatment program.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">While the indications for use of a dose-intensive strategy, and the ultimate clinical course, differed in the three patients, collectively these cases raise relevant questions regarding optimal management of high risk and recurrent GTD.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The experience represented in this report support the earlier use of cisplatin-based chemotherapy in the management of high-risk and recurrent GTD, and the possible administration of a high-dose chemotherapy program in the rare patient who recurs following &quot;standard dose&quot; platinum-based treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Markman</LastName>
                    <ForeName>Maurie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, (Mail Box # 121), Houston, TX 77030-4009, USA. mmarkman@mdanderson.org</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
            <NlmUniqueID>7902060</NlmUniqueID>
            <ISSNLinking>0171-5216</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6PLQ3CP4P3</RegistryNumber>
                <NameOfSubstance UI="D005047">Etoposide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005047" MajorTopicYN="N">Etoposide</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D031901" MajorTopicYN="N">Gestational Trophoblastic Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014594" MajorTopicYN="N">Uterine Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>28</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15150657</ArticleId>
            <ArticleId IdType="doi">10.1007/s00432-004-0568-5</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 1995 Feb;56(2):231-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7534740</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 1993 Feb;7(2):152-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8426468</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1996 Oct;14(10):2638-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8874322</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1991 Aug 1;68(3):600-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1648435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1985 Sep 15;56(6):1341-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2411377</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1994 Jun;12(6):1223-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7911158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1990 Apr;8(4):715-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1690272</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1995 Feb 1;75(3):874-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7828139</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1986 May 1;57(9):1731-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2420435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Oct;16(10):3386-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9779717</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1995 Sep;58(3):383-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7672706</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2002 Jul 15;95(2):309-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12124831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1987 Jun 4;316(23):1435-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2437455</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1997 May;65(2):366-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9159354</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hematol Oncol Clin North Am. 1999 Feb;13(1):225-44, x</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10080078</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Jul;15(7):2636-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9215835</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Nov 15;21(22):4073-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14568986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 Aug;18(16):2957-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10944128</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Mar 15;21(6):1074-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12637473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1991 Dec 12;325(24):1682-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1944468</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2001 Jan 1;19(1):81-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11134198</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 Oct 1;18(19):3346-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11013274</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1994 Feb;12(2):378-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8113845</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 Mar;18(6):1173-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10715285</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 1989 Jul 1;111(1):22-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2472080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1994 Apr;12(4):701-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7512129</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Apr;15(4):1583-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9193356</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
